In addition, Orexigen has granted the underwriters a 30-day option to purchase an additional 1.05 million shares to cover overallotments, if any.
Merrill Lynch & Co. acted as sole book-running manager and Leerink Swann acted as co-lead manager for the offering. JMP Securities, Lazard Capital Markets, Canaccord Adams and Natixis Bleichroeder acted as co-managers for the offering.